日本Miraca Life Sciences  
miraca生命科学专家病理学服务提供的信息，他们需要做出重要的个体化治疗决策的医生。我们相信，更好的信息，可能导??致更有效的治疗方法的选择，并最终以更好的结果与癌症和其他复杂疾病的患者。

miraca提供皮肤病，肠胃病学，血液学和泌尿系统等领域的专科病理解剖服务。我们还提供普通外科病理学服务。

我们的专家有良好记录的准确诊断困难的??情况下 - 区分类似条件，准确地识别药物和其他因素的影响。

我们的许多病理学家全国领导机构的教职员工，并积极参与研究的举措。通过严格的质量保证，每天的会议，并与临床合作伙伴的密切关系，我们不断提高我们服务的每一天，成千上万患者的诊断精度。

miraca生命科学是Miraca控股公司，日本最大的临床诊断和实验室测试服务供应商的子公司。卡里斯诊断，以前，该公司更名为2012年2月Miraca生命科学。
 

Miraca Life Sciences' expert pathology services provide physicians with the information they need to make important individualized treatment decisions. We believe that better information can lead to more effective treatment selection and ultimately to better outcomes for patients with cancer and other complex diseases.

Miraca provides subspecialty anatomic pathology services in the fields of dermatology, gastroenterology, hematology and urology. We also offer general surgery pathology services.

Our specialists have a proven track record of accurately diagnosing difficult cases — from distinguishing between similar conditions to accurately identifying the effects of medications and other factors.

Many of our pathologists are faculty members at leading institutions nationwide and actively participate in research initiatives. Through rigorous quality assurance, daily conferences, and close relationships with clinical partners, we continuously improve diagnostic precision for the thousands of patients we serve each day.

Miraca Life Sciences is a subsidiary of Miraca Holdings, Inc., Japan’s largest clinical diagnostics and laboratory testing service provider. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012.

About Miraca Life Sciences
Miraca Life Sciences specializes in the development and commercialization of the highest quality anatomic pathology services, primarily in the fields of dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company’s core team of more than 70 world-leading, academic-caliber specialists utilize state of the art pathology laboratories currently headquartered in Irving, Texas, and throughout the United States to serve more than 3,000 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.

About Miraca Holdings
With group net sales of ¥165.7 billion (FYE 3/2010), Miraca Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in vitro diagnostics in Japan, and SRL, Inc. ("SRL"), Japan's largest commercial laboratory. SRL offers comprehensive clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.